Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for prevention of necrotising enterocolitis progression in preterm neonates
ACTRN12606000257561Phase 3Withdrawn
- Sponsor
- King Edward Memorial Hospital
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in necrotizing enterocolitis (NEC) comparing Pentoxifylline with Placebo (2 arms). Primary endpoint: Safety and efficacy of pentoxifylline in preventing progression of NEC to stage III and/or death. Planned start Sep 2006; status: withdrawn.
02
Drugs
pentoxifylline
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on ACTRN12606000257561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000257561.